1. |
魏世辉, 宋宏鲁. 增强对视神经脊髓炎相关性视神经炎的认识, 提高早期正确诊断及治疗水平[J]. 中华眼底病杂志, 2019, 35(3): 215-218. DOI: 10.3760/cma.j.issn.1005-1015.2019.03.001.Wei SH, Song HL. Enhance the awareness of neuromyelitis optica-related optic neuritis to improve early diagnosis and treatment outcomes[J]. Chin J Ocul Fundus Dis, 2019, 35(3): 215-218. DOI: 10.3760/cma.j.issn.1005-1015.2019.03.001.
|
2. |
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis[J]. Lancet, 2004, 364(9451): 2106-2112. DOI: 10.1016/S0140-6736(04)17551-X.
|
3. |
Zhou H, Zhao S, Yin D, et al. Optic neuritis: a 5-year follow-up study of chinese patients based on aquaporin-4 antibody status and ages[J]. J Neurol, 2016, 263(7): 1-8. DOI: 10.1007/s00415-016-8155-7.
|
4. |
Kang H, Chen T, Li H, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive chinese patients with acute optic neuritis[J]. J Neurol, 2017, 264(10): 2130-2140. DOI: 10.1007/s00415-017-8606-9.
|
5. |
中华医学会眼科学分会神经眼科学组. 视神经炎诊断和治疗专家共识(2014年)[J]. 中华眼科杂志, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.Neuro-ophthalmology Group, Ophthalmological Branch, Chinese Medical Association. Expert consensus on diagnosis and treatment of optic neuritis(2014)[J]. Chin J Ophthalmol, 2014, 50(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.
|
6. |
Song H, Zhou H, Mo Y, et al. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in china[J]. Br J Ophthalmol, 2019, 103(6): 831-836. DOI: 10.1136/bjophthalmol-2018-312399.
|
7. |
Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study[J]. JAMA Neurol, 2014, 71(3): 276-283. DOI: 10.1001/jamaneurol.2013.5857.
|
8. |
宋宏鲁, 周欢粉, 杨沫, 等. 儿童髓鞘少突胶质细胞糖蛋白抗体阳性视神经炎临床特点分析[J]. 解放军医学院学报, 2019, 40(5): 305-310. DOI: 10.3969/j.issn.2095-5227.2019.04.002.Song HL, Zhou HF, Yang M, et al. Clinical features of myelin oligodendrocyte glycoprotein antibody-positive pediatric optic neuritis[J]. Acad J Chin PLA Med Sch, 2019, 40(5): 305-310. DOI: 10.3969/j.issn.2095-5227.2019.04.002.
|
9. |
Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome[J]. Am J Ophthalmol, 2018, 195: 8-15. DOI: 10.1016/j.ajo.2018.07.020.
|
10. |
Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing mog antibody-associated demyelination[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2): 127-137. DOI: 10.1136/jnnp-2017-316880.
|
11. |
Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with aqp4 or mog in neuromyelitis optica spectrum disorders[J]. Ther Adv Neurol Disord, 2016, 9(5): 436-440. DOI: 10.1177/1756285616655264.
|
12. |
Nakajima H, Motomura M, Tanaka K, et al.Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis[J/OL]. BMJ Open, 2015, 5(4): 007766[2015-04-02]. http://dx.doi.org/10.1136/bmjopen-2015-007766. DOI: 10.1136/bmjopen-2015-007766.
|
13. |
宋宏鲁, 魏世辉. 髓鞘少突胶质细胞糖蛋白抗体阳性视神经炎的临床特征分析[J]. 中华眼科杂志, 2019, 55(3): 174-179. DOI: 10.3760/cma.j.issn.0412-4081.2019.03.005.Song HL, Wei SH. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody- positive optic neuritis[J]. Chin J Ophthalmol, 2019, 55(3): 174-179. DOI: 10.3760/cma.j.issn.0412-4081.2019.03.005.
|
14. |
Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis[J]. Mult Scler, 2016, 22(4): 470-482. DOI: 10.1177/1352458515593406.
|
15. |
Lock JH, Newman NJ, Blouse V, et al. Update on pediatric optic neuritis[J]. Cur Opin Ophthalmol, 2019, 30(6): 418-425. DOI: 10.1097/ICU.0000000000000607.
|
16. |
Longoni G, Banwell B, Filippi M, et al. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children[J/OL]. Neurol Neuroimmunol Neuroinflamm, 2014, 1(4): 46[2014-12-11]. https://nn.neurology.org/content/1/4/e46.long. DOI: 10.1212/NXI.0000000000000046.
|
17. |
Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report[J]. Neurology, 2016, 86(3): 245-252. DOI: 10.1212/WNL.0000000000002283.
|
18. |
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189. DOI: 10.1212/WNL.0000000000001729.
|